The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice

Rafael Bayarri-Olmos, Laust Bruun Johnsen, Manja Idorn, Line S Reinert, Anne Rosbjerg, Søren Vang, Cecilie Bo Hansen, Charlotte Helgstrand, Jais Rose Bjelke, Theresa Bak-Thomsen, Søren R Paludan, Peter Garred, Mikkel-Ole Skjoedt*

*Corresponding author af dette arbejde

Abstract

The alpha/B.1.1.7 SARS-CoV-2 lineage emerged in autumn 2020 in the United Kingdom and transmitted rapidly until winter 2021 when it was responsible for most new COVID-19 cases in many European countries. The incidence domination was likely due to a fitness advantage that could be driven by the receptor-binding domain (RBD) residue change (N501Y), which also emerged independently in other variants of concern such as the beta/B.1.351 and gamma/P.1 strains. Here, we present a functional characterization of the alpha/B.1.1.7 variant and show an eightfold affinity increase towards human angiotensin-converting enzyme-2 (ACE-2). In accordance with this, transgenic hACE2 mice showed a faster disease progression and severity after infection with a low dose of B.1.1.7, compared to an early 2020 SARS-CoV-2 isolate. When challenged with sera from convalescent individuals or anti-RBD monoclonal antibodies, the N501Y variant showed a minor, but significant elevated evasion potential of ACE-2/RBD antibody neutralization. The data suggest that the single asparagine to tyrosine substitution remarkable rise in affinity may be responsible for the higher transmission rate and severity of the B.1.1.7 variant.

OriginalsprogEngelsk
Artikelnummer:e70002
TidsskrifteLife
Vol/bind10
ISSN2050-084X
DOI
StatusUdgivet - 25 nov. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice'. Sammen danner de et unikt fingeraftryk.

Citationsformater